BidaskClub upgraded shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) from a strong sell rating to a sell rating in a report issued on Wednesday.

Other analysts have also issued reports about the stock. Maxim Group set a $7.00 price target on shares of Achillion Pharmaceuticals and gave the stock a buy rating in a research report on Wednesday, August 9th. Zacks Investment Research lowered shares of Achillion Pharmaceuticals from a buy rating to a hold rating in a research report on Wednesday, May 10th. Jefferies Group LLC reaffirmed a hold rating on shares of Achillion Pharmaceuticals in a research report on Wednesday, April 26th. Robert W. Baird lowered shares of Achillion Pharmaceuticals from an outperform rating to a neutral rating and set a $5.00 price objective on the stock. in a research report on Thursday, August 10th. Finally, Chardan Capital cut their price objective on shares of Achillion Pharmaceuticals from $5.00 to $4.00 and set a neutral rating on the stock in a research report on Wednesday, August 9th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and five have issued a buy rating to the company’s stock. Achillion Pharmaceuticals presently has a consensus rating of Hold and an average target price of $8.25.

Shares of Achillion Pharmaceuticals (NASDAQ ACHN) traded down 4.30% during trading on Wednesday, reaching $4.67. 1,489,155 shares of the company traded hands. The firm has a 50-day moving average price of $4.45 and a 200-day moving average price of $4.16. Achillion Pharmaceuticals has a 12 month low of $3.15 and a 12 month high of $9.49. The firm’s market capitalization is $638.67 million.

Achillion Pharmaceuticals (NASDAQ:ACHN) last posted its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.16). During the same quarter in the previous year, the business earned ($0.14) earnings per share. Equities research analysts anticipate that Achillion Pharmaceuticals will post ($0.63) EPS for the current year.

TRADEMARK VIOLATION WARNING: “BidaskClub Upgrades Achillion Pharmaceuticals, Inc. (ACHN) to Sell” was published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this article on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The correct version of this article can be read at https://theolympiareport.com/2017/08/20/bidaskclub-upgrades-achillion-pharmaceuticals-inc-achn-to-sell.html.

Institutional investors have recently modified their holdings of the stock. Parametric Portfolio Associates LLC raised its position in shares of Achillion Pharmaceuticals by 304.7% in the first quarter. Parametric Portfolio Associates LLC now owns 103,263 shares of the biopharmaceutical company’s stock valued at $435,000 after buying an additional 77,748 shares during the last quarter. Teza Capital Management LLC bought a new position in shares of Achillion Pharmaceuticals during the first quarter valued at approximately $131,000. UBS Asset Management Americas Inc. increased its position in shares of Achillion Pharmaceuticals by 83.8% in the first quarter. UBS Asset Management Americas Inc. now owns 53,669 shares of the biopharmaceutical company’s stock valued at $226,000 after buying an additional 24,471 shares during the period. Canada Pension Plan Investment Board increased its position in shares of Achillion Pharmaceuticals by 4.7% in the first quarter. Canada Pension Plan Investment Board now owns 35,800 shares of the biopharmaceutical company’s stock valued at $151,000 after buying an additional 1,600 shares during the period. Finally, Wells Fargo & Company MN increased its position in shares of Achillion Pharmaceuticals by 11.9% in the first quarter. Wells Fargo & Company MN now owns 215,820 shares of the biopharmaceutical company’s stock valued at $908,000 after buying an additional 22,931 shares during the period. 70.70% of the stock is currently owned by hedge funds and other institutional investors.

About Achillion Pharmaceuticals

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.

Analyst Recommendations for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.